Free Trial
LON:AZN

AstraZeneca (AZN) Share Price, News & Analysis

AstraZeneca logo
GBX 9,946 -23.00 (-0.23%)
(As of 03:32 AM ET)

About AstraZeneca Stock (LON:AZN)

Key Stats

Today's Range
9,867
£100.88
50-Day Range
9,725
£127.12
52-Week Range
9,461
£133.88
Volume
57.53 million shs
Average Volume
4.17 million shs
Market Capitalization
£154.16 billion
P/E Ratio
3,157.46
Dividend Yield
2.35%
Price Target
£104.12
Consensus Rating
Moderate Buy

Company Overview

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

AstraZeneca Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
45th Percentile Overall Score

AZN MarketRank™: 

AstraZeneca scored higher than 45% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    AstraZeneca has received a consensus rating of Moderate Buy. The company's average rating score is 2.56, and is based on 6 buy ratings, 2 hold ratings, and 1 sell rating.

  • Amount of Analyst Coverage

    AstraZeneca has only been the subject of 4 research reports in the past 90 days.

  • Read more about AstraZeneca's stock forecast and price target.
  • Price to Earnings Ratio vs. the Market

    The P/E ratio of AstraZeneca is 3,157.46, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 134.38.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of AstraZeneca is 3,157.46, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 130.53.

  • Price to Earnings Growth Ratio

    AstraZeneca has a PEG Ratio of 0.86. PEG Ratios below 1 indicate that a company could be undervalued.

  • Price to Book Value per Share Ratio

    AstraZeneca has a P/B Ratio of 3.90. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Short Interest

    There is no current short interest data available for AZN.
  • Dividend Yield

    AstraZeneca pays a meaningful dividend of 1.97%, higher than the bottom 25% of all stocks that pay dividends.

  • Dividend Growth

    AstraZeneca does not have a long track record of dividend growth.

  • Dividend Coverage

    The dividend payout ratio of AstraZeneca is 7,428.57%. Payout ratios above 75% are not desirable because they may not be sustainable.

  • Read more about AstraZeneca's dividend.
  • Short Interest

    There is no current short interest data available for AZN.
  • News Sentiment

    AstraZeneca has a news sentiment score of 0.61. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.45 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 10 news articles for AstraZeneca this week, compared to 2 articles on an average week.
  • Search Interest

    37 people have searched for AZN on MarketBeat in the last 30 days. This is an increase of 208% compared to the previous 30 days.
  • MarketBeat Follows

    5 people have added AstraZeneca to their MarketBeat watchlist in the last 30 days. This is an increase of 400% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, AstraZeneca insiders have bought more of their company's stock than they have sold. Specifically, they have bought £2,233,160 in company stock and sold GBX 0 in company stock.

  • Percentage Held by Insiders

    Only 0.04% of the stock of AstraZeneca is held by insiders.

  • Percentage Held by Institutions

    51.03% of the stock of AstraZeneca is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about AstraZeneca's insider trading history.
Receive AZN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AstraZeneca and its competitors with MarketBeat's FREE daily newsletter.

AZN Stock News Headlines

Top "Sleeping Giant" Crypto In The Market Now
Top "Sleeping Giant" Crypto In The Market Now We're looking at potential returns that could rewrite your financial future.
AstraZeneca PLC (LON:AZN) Insider Acquires £2,040,600 in Stock
AstraZeneca put volume heavy and directionally bearish
See More Headlines

AZN Stock Analysis - Frequently Asked Questions

AstraZeneca's stock was trading at £106 at the beginning of 2024. Since then, AZN shares have decreased by 6.2% and is now trading at GBX 9,946.
View the best growth stocks for 2024 here
.

Shares of AZN stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that AstraZeneca investors own include GSK (GSK), NVIDIA (NVDA), Meta Platforms (META), Tesla (TSLA), Intel (INTC), Advanced Micro Devices (AMD) and Johnson & Johnson (JNJ).

Company Calendar

Ex-Dividend for 9/9 Dividend
8/08/2024
Dividend Payable
9/09/2024
Today
11/20/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Drug Manufacturers—General
Sub-Industry
Pharmaceutical Products
CIK
N/A
Fax
N/A
Employees
83,500
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
£104.12
High Stock Price Target
£150
Low Stock Price Target
GBX 74
Potential Upside/Downside
+4.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.56
Research Coverage
9 Analysts

Profitability

Net Income
£6.44 billion
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
£49.13 billion
Cash Flow
GBX 256.33 per share
Book Value
GBX 2,549 per share

Miscellaneous

Outstanding Shares
1,550,000,000
Free Float
N/A
Market Cap
£154.52 billion
Optionable
Not Optionable
Beta
0.17
Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link below to learn more about using beta to protect yourself.

Get This Free Report

This page (LON:AZN) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners